Health Alert:

COVID-19 Information

UPMC HIllman Cancer Center Neuro Oncology Clinical Studies

Brain and Nervous System Cancer Clinical Trials and Research

Doctors at UPMC Hillman Cancer Center work with top scientists across the U.S. to:

  • Advance research into promising new treatments for brain and nervous system cancers.
  • Study more people in each trial so we can learn faster.
  • Gives people who come to UPMC Hillman for care access to more trials.

All brain cancer treatments we use now are the result of past clinical trials.

At UPMC, we invest in cancer research because we want to improve survival rates and quality of life for people.

Current Brain and Nervous System Tumor Trials

Doctors at UPMC Hillman's Neuro-Oncology Program are leading more than 15 studies. Click on any trial's number to see details on the U.S. National Institutes of Health (NIH) clinical trials website.

Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating People With Newly Diagnosed Glioblastoma.

Olaparib in Treating Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations.

Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in People With Brain Cancer.

A Trial to Assess Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma (GBM AGILE).

A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy.

BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations.

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy). Study for People with Newly Diagnosed MGMT Unmethylated Glioblastoma.

A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioblastoma With Elevated Mutational Burden.

Study of Vorasidenib (AG-881) in People With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO).

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers.

Phase 1 Open-Label Study of Genetically Engineered Oncolytic HSV-1 (C5252) Expressing IL-12 and Anti-PD-1 Antibody. Trial for Peoples with Recurrent or Progressive Malignant Glioblastoma.

Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM (EF-32).

A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma.

A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy. Study for People With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1.

Fractionated Stereotactic Radiosurgery for Large Brain Metastases.

A Study of Erdafitinib in People With Advanced Solid Tumors and Fibroblast Growth Factor Receptor Gene Alterations.

Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors.

Contact the Neuro-Oncology Program to Make an Appointment

To learn more about brain and nervous system cancer or to make an appointment, you can:

Fill out our online contact form.